A case of dMMR/MSI-H/TMB-H colon cancer with brain metastasis treated with PD-1 monoclonal antibody

Tao Xiang, H. Zhang, Weijia Fang, Wen‐Bin ChenJournal of Zhejiang University (Medical Sciences) 2024 · DOI

This case report, published in the Journal of Zhejiang University (Medical Sciences) in February 2024, details a remarkable clinical success: the complete remission of brain-metastatic colon cancer using immunotherapy.

TL;DR

Researchers report a rare case of a 70-year-old colon cancer patient with brain metastasis who achieved a complete clinical response (cCR) using the PD-1 inhibitor pembrolizumab. Despite failing standard chemotherapy, the patient’s specific genetic profile—characterized by mismatch repair deficiency (dMMR) and high tumor mutation burden (TMB-H)—made him an ideal candidate for immunotherapy, leading to the total disappearance of his brain lesions.

What Problem Does This Paper Address?

Colorectal cancer (CRC) rarely spreads to the brain, occurring in only about 0.06% to 4% of patients. However, when it does, the prognosis is grim, with median survival typically ranging from only 3 to 6 months.

The primary challenge is the blood-brain barrier (BBB), which prevents most standard chemotherapy drugs from reaching the tumor in effective concentrations. While immunotherapy has revolutionized the treatment of "hot" tumors (those with many mutations), its efficacy against brain metastases specifically originating from colon cancer has not been extensively documented. This paper explores whether PD-1 inhibitors can overcome these physiological and pharmacological hurdles in a patient with a specific genetic signature.

Methods

The paper follows a single-patient clinical course using a multi-modal diagnostic and therapeutic approach:

  • Surgical Intervention: Radical resection of the primary colon tumor followed by surgical removal of the brain metastasis when it appeared a year later.
  • Pathology & Biomarker Testing: Immunohistochemistry (IHC) was used to check for Mismatch Repair (MMR) proteins. Next-Generation Sequencing (NGS) was employed to determine Microsatellite Instability (MSI) status and Tumor Mutation Burden (TMB).
  • Immunotherapy: After the patient relapsed following standard XELOX chemotherapy (oxaliplatin and capecitabine), he was treated with pembrolizumab (200 mg every three weeks).
  • Monitoring: The response was tracked via serial MRI scans, PET-CT, and monitoring of the tumor marker Carcinoembryonic Antigen (CEA).

Datasets

As a clinical case report, the "dataset" consists of the longitudinal clinical data from a single 70-year-old male patient. This includes:

  • Imaging: Pre- and post-treatment MRI and PET-CT scans.
  • Genomic Data: NGS results showing a TMB of 77.7 muts/Mb and MSI-H status.
  • Biochemical Markers: A timeline of CEA levels (ranging from 8.2 to 19 ng/mL during recurrence, dropping to normal post-treatment).

Key Insights and Ideas

  • The Power of dMMR/MSI-H: The patient’s tumor was "mismatch repair deficient" (dMMR). This means the cancer cells couldn't fix DNA errors, leading to a "high tumor mutation burden" (TMB-H). These mutations create "neoantigens"—proteins that look foreign to the immune system—essentially "painting a target" on the cancer cells for T-cells to find.
  • Immunotherapy vs. The Blood-Brain Barrier: While large monoclonal antibodies like pembrolizumab have poor BBB penetration, they work by activating T-cells in the periphery. These activated T-cells can cross into the central nervous system, especially where the BBB is disrupted by the tumor itself, to exert an anti-tumor effect.
  • Chemotherapy Resistance: The brain metastasis relapsed just one month after the patient finished adjuvant chemotherapy. This highlights that for dMMR/MSI-H tumors, traditional cytotoxic drugs may be significantly less effective than targeted immunotherapy.

Key Results

  • Complete Clinical Response (cCR): After just four cycles of pembrolizumab, MRI scans showed that the brain metastatic lesions had completely shrunk.
  • Biomarker Normalization: The patient’s CEA levels, which had spiked to 19 ng/mL during the relapse, returned to the normal range by the 10th cycle of treatment.
  • Long-term Survival: At the time of the report, the patient had completed 16 cycles of immunotherapy and remained in remission for nearly a year with no signs of recurrence.
  • Safety: The treatment was well-tolerated, with only mild (Grade 1-2) skin rashes reported as side effects.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Case: While the results are dramatic, they come from one patient. Large-scale clinical trials are needed to confirm if this success rate is reproducible across a broader population of CRC patients with brain metastases.
  • Missing Genomic Comparison: While the primary tumor was sequenced, the researchers were unable to perform repeat sequencing on the relapsed brain lesion to see if its mutational profile had evolved.
  • Future Directions: The study suggests that dMMR/MSI-H/TMB-H status should be routinely screened in CRC patients with brain metastases, as it may identify a subset of patients who could achieve long-term survival through immunotherapy rather than palliative care.

Summary updated

Abstract

A 70-year-old man had radical surgery for colon cancer one year before the symptoms of memory loss and decreasing cognitive function. Subsequent magnetic resonance imaging revealed a brain mass, which was surgically resected and confirmed to be metastatic intestinal adenocarcinoma. Immunohistochemistry of the primary tumor and brain metastasis showed mismatch repair deficiency. The patient received adjuvant chemotherapy after surgery. However, the brain metastasis relapsed one month after the last chemotherapy. Genetic testing on the resected colon tumor samples confirmed microsatellite instability-high with a high tumor mutation burden by 77.7 muts/Mb. The patient was subsequently treated with programmed death-1 (PD-1) monoclonal antibody pembrolizumab (keytruda). The brain metastatic lesions were completely shrunk, and a complete clinical response was achieved.
BibTeX
@article{xiang2024case,
  author = {Tao Xiang and H. Zhang and Weijia Fang and Wen‐Bin Chen},
  title = {{A case of dMMR/MSI-H/TMB-H colon cancer with brain metastasis treated with PD-1 monoclonal antibody}},
  journal = {Journal of Zhejiang University (Medical Sciences)},
  year = {2024},
  doi = {10.3724/zdxbyxb-2023-0547},
}
Figure